Reetu Mukherji, MD
Hematology & Oncology · Washington, DCNPI 1861846875
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AstraZeneca at 42.6% of the total. 2025 is the largest year on record at $13,831, more than ten times the $195 reported in 2022.
Across 45 payments — averaging $332.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Astellas Pharma Global Development$2K
- Boston Scientific$2K
- Gilead$2K
- Astellas Pharma US Inc$1K
- Intera Oncology, Inc$281
- plus $928 from 13 others
Across 10 payments — averaging $31,573 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$165K
- Boston Scientific$101K
- Astrazeneca UK Limited$34K
- Genentech, Inc.$15K
What the payments were for
- Consulting fees$5,25235%
- Speaking & faculty fees$5,77039%
- Travel & lodging$6254%
- Food & beverage$2,74118%
- Education$5874%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $6,385 |
| Astellas Pharma Global Development | 2 | $2,179 |
| Boston Scientific | 6 | $2,008 |
| Gilead | 1 | $1,740 |
| Astellas Pharma US Inc | 4 | $1,454 |
| Intera Oncology, Inc | 2 | $281 |
| Beone Medicines USA, Inc. | 3 | $181 |
| Jazz Pharmaceuticals Inc. | 1 | $175 |
| Seagen Inc. | 2 | $155 |
| Novartis | 3 | $79 |
| Sanofi | 2 | $78 |
| Genentech, Inc. | 1 | $53 |
| Johnson & Johnson | 2 | $50 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Daiichi Sankyo Inc. | 1 | $29 |
| GSK | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$4,320
- Vyloy$3,297
- TheraSphere Y90 Glass Microspheres 10 GBq$2,008
- INTERA$214
How this compares
$14,976 in reported general payments places this provider in the 70th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enoxaparin Sodium | 12 | $2,611 |
| Prochlorperazine Maleate | 24 | $692 |
| Ondansetron Hcl | 46 | $664 |
| Potassium Chloride | 13 | $391 |
| Oxycodone Hcl | 20 | $258 |
| Dexamethasone | 11 | $242 |
| Famotidine | 14 | $84 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.